Navigation Links
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
Date:5/11/2009

PARSIPPANY, N.J., May 11 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the use of AR-12, a potentially first-in-class, orally available, PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the endoplasmic reticulum stress pathway. Acceptance of the IND permits Arno to initiate a Phase I clinical trial in adults with advanced or recurrent solid tumors or lymphoma for which no standard therapy is available. Arno expects the Phase I clinical trial to begin during the second half of 2009 and will be designed to assess the safety and early evidence of activity of AR-12.

"We are excited that AR-12 has received IND acceptance by the FDA allowing us to begin our Phase I studies. Our preclinical data has demonstrated that AR-12 is active in a wide range of tumor types and it also shows promising activity in combination with several widely used approved cytotoxic as well as molecularly targeted anti-cancer agents," stated Dr. Roger G. Berlin, Chief Executive Officer of Arno.

About AR-12

AR-12 is a potentially first-in-class, orally available, PDK1 inhibitor that blocks the PI3K/Akt pathway and induces the endoplasmic reticulum stress pathway.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead clinical development compound is AR-67, a novel, third-generation camptothecin analogue which has completed patient enrollment of its Phase I studies in patients with advanced solid tumors, that has demonstrated high preclinical potency and improved pharmacokinetic properties when compared with marketed second-g
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
2. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
9. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
10. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 PuraMed BioScience ® ... of over-the-counter (OTC) medicinal and healthcare products, announced ... M name along with the name,s red and ... the trademarked name MigraPure ®  going forward. ... PuraMed,s homeopathic, natural migraine pain reliever will be ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... 2011 Reportlinker.com announces that a new market research ... Epidemiology: Lupus http://www.reportlinker.com/p0484924/Epidemiology-Lupus.html ... 404,300 prevalent cases of systemic lupus erythematosus (SLE) in ... cases in women between 45 and 64 years of ...
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... manufacturing, and marketing of branded generic and proprietary pharmaceuticals ... unaudited financial results for the first quarter ended March ... market opens in the United States. Simcere,s management will ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Lupus 2Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011 2
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... want to help their preschooler shed excess pounds may want ... Youngsters whose parents joined them in a supervised behavioral modification ... in a traditional child-only program (an average difference of about ... losing almost 15 pounds over two years, according to the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The family ... bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... thinner, Bernstein Liebhard LLP reports. According to the complaint, ... District of Vermont on July 25th, the decedent had ... suffered an irreversible brain bleed that ultimately led to ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
(Date:7/30/2014)... McLean, VA (PRWEB) July 30, 2014 ... its 2014-2015 Board of Directors. Sandra Aiken Chack will ... this month at the EDNF 2014 Annual Learning Conference ... National Foundation has an ambitious agenda ahead of us. ... Clinical Care & Research at the Greater Baltimore Medical ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and ... 4 p.m. to 7 p.m. Wednesday, August 6 at ... Livonia, MI 48152). The event will feature Detroit Red ... music, snacks and local public safety officials. Kohl’s will ... of Michigan Foundation. , The gift supports Kohl’s ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... Paralleling the nation,s efforts to find ways to expand ... care, Concierge Choice Physicians (CCP) announced in ... physicians care for more than 250,000 patients in 12 states - ... Pioneering the concept of hybrid concierge medicine, CCP offers primary care ...
... EAST HAMPTON, N.Y., July 8 The Max Cure Foundation ... cancer causes -- announced today its first charity benefit, the ... day, to take place on Saturday, August 22, from 2:00 ... grounds of the East Hampton Indoor Tennis Club, 175 Daniels ...
... 8 Insulet Corporation (Nasdaq: PODD ), ... that the Company is introducing an environmentally friendly disposal ... Eco-Pod program will reduce the impact of used Pods ... landfills. It is the industry,s first program for ...
... the most famous hotels in Coconut Grove, Florida is now offering ... , In the spirit of game shows of yesterday and today, ... Deal special. It,s simple...call the hotel, mention the Let,s Make a ... suites...the hotel may counter with a Deal or No Deal offer, ...
... July 8 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended June 30, 2009, on Thursday, August 6, ... a conference call and webcast on Thursday, August 6, ... Company,s second quarter results and current corporate developments. The dial-in number ...
... July 8 You,ve just waited through the longest two minutes ... to be positive. After catching your breath, you realize the only ... same again. That,s because you,ve just learned you,re pregnant! This discovery ... mind, and you know you need fast answers. That,s when you ...
Cached Medicine News:Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 2Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System 2Health News:A Unique Rhythm In The Heart Of Coconut Grove, Florida 2Health News:Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:A Bundle of Joy Brings a Bundle of Questions - Life123.com Delivers the Answers! 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
For the quantitative determination of aspartate aminotransferase (AST) in human serum. The reagents are used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: